OncoScience is a leading company in the field of oncology, dedicated to developing innovative treatment options for rare diseases. With a focus on oncology and orphan drugs, they aim to address the significant impact of cancer, which remains one of the leading causes of death globally. As part of their commitment to advancing cancer care, OncoScience collaborates with Specific Pharma A/S to provide a Named Patient Program for cancer treatment with nimotuzumab.

Nimotuzumab has shown promising results in various clinical studies, benefiting patients with Diffuse Intrinsic Pontine Glioma (DIPG) and locally advanced or metastatic Pancreatic Carcinoma. With a strong emphasis on research and development, OncoScience is at the forefront of innovative therapies to improve patient outcomes. Through their dedication and expertise, they strive to make a positive impact in the lives of cancer patients worldwide.

For more information about their products and services, visit their website